Clinical Trial Update: Primary Cardiovascular Risk Prevention With Aspirin in Chronic Kidney Disease Patients [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial update evaluating aspirin for primary cardiovascular risk prevention in adults with chronic kidney disease (stages 3 and 4).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease

Drugs mentioned

• Aspirin (Aspirin)

Snippet

Sponsor: Fundación de Ayuda a la Investigación sobre la Hipertensión, Riesgo Cardiovascular y Enfermedades Renales | Conditions: Chronic Kidney Disease Stage 4, Chronic Kidney Disease Stage 3 | Phase 3 | Status: UNKNOWN